Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration

被引：4
|
作者：
Marin, Ellen [1 ]
Scott, Sara [2 ]
Maples, Kathryn [3 ]
Joseph, Nisha S. [4 ]
Hofmeister, Craig C. [5 ]
Gupta, Vikas A. [5 ]
Dhodapkar, Madhav V. [5 ]
Kaufman, Jonathan L. [5 ]
Lonial, Sagar [6 ]
Nooka, Ajay K. [2 ]
机构：
[1] Emory Univ Hosp, Winship Canc Inst, Decatur, GA USA
[2] Emory Univ Hosp, Winship Canc Inst, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[3] Pfizer, Atlanta, GA USA
[4] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[6] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189878
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Real world experience of teclistamab using a prompt management strategy for cytokine release syndrome
    Catamero, Donna
    Dai, Victoria
    Rattu, Mohammad
    Jagannath, Sundar
    Rodriguez, Cesar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S309 - S310
  • [22] CAR T Therapy for Lymphoma With Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome Without Excessive Neurologic Toxicity
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 10 - 11
  • [23] The effect of tocilizumab on cytokine release syndrome in COVID-19 patients
    Carmen de Cáceres
    Rodrigo Martínez
    Pablo Bachiller
    Laura Marín
    José Manuel García
    Pharmacological Reports, 2020, 72 : 1529 - 1537
  • [24] Tocilizumab Treatment in COVID-19-induced Cytokine Release Syndrome
    Algazaq, Jumanah
    Hiraldo-Infante, Cristian
    Miskovsky, John
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2020, 28 (06) : E76 - E78
  • [25] Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19
    Hassoun, Ali
    Thottacherry, Elizabeth Dilip
    Muklewicz, Justin
    Aziz, Qurrat-ul-Ain
    Edwards, Jonathan
    JOURNAL OF CLINICAL VIROLOGY, 2020, 128
  • [26] The effect of tocilizumab on cytokine release syndrome in COVID-19 patients
    de Caceres, Carmen
    Martinez, Rodrigo
    Bachiller, Pablo
    Marin, Laura
    Garcia, Jose Manuel
    PHARMACOLOGICAL REPORTS, 2020, 72 (06) : 1529 - 1537
  • [27] EARLY ADMINISTRATION OF TOCILIZUMAB (TOCI) FOR THE PREVENTION OF GRADE 4 CYTOKINE RELEASE SYNDROME (CRS) AFTER CD19-DIRECTED CAR T-CELL THERAPY (CTL019)
    Kadauke, S.
    Maude, S.
    Gladney, W.
    Motley, L.
    Shenoy, V.
    Callahan, C.
    Baniewicz, D.
    Teachey, D. T.
    Grupp, S.
    DiNofia, A.
    CYTOTHERAPY, 2019, 21 (05) : E2 - E3
  • [28] The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy
    Peaytt, Rachel
    Parsons, Laura Beth
    Siler, Darby
    Matthews, Rachel
    Li, Belinda
    Bell, David
    Bachier, Carlos
    Pantin, Jeremy
    Berdeja, Jesus
    Flinn, Ian
    Donnellan, William
    Battiwalla, Minoo
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 45 - 51
  • [29] Utilizing quantitative systems pharmacology (QSP) model to understand cytokine release syndrome (CRS) following administration of epcoritamab in DLBCL patients
    Afzal, Nasrin
    Li, Tommy
    Chiu, Christopher
    Sacchi, Mariana
    Gupta, Manish
    Xu, Steven
    Thalhauser, Craig J.
    CANCER RESEARCH, 2023, 83 (07)
  • [30] CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity
    Caimi, Paolo F.
    Sharma, Ashish
    Rojas, Patricio
    Patel, Seema
    Reese, Jane
    Otegbeye, Folashade
    Worden, Andrew
    Kadan, Michael
    Maschan, Michael
    Orentas, Rimas J.
    Dropulic, Boro
    Sekaly, Rafick
    de Lima, Marcos
    BLOOD, 2020, 136
12345